62367-59-3

Basic information

• Product Name: (S)-3-Hydroxy-1-methyl-piperidine
• Synonyms: (S)-3-Hydroxy-1-methyl-piperidine;(S)-3-Hydroxy-1-Methyl-pi...;(3S)-1-methylpiperidin-3-ol
• CAS NO: 62367-59-3
• Molecular Formula: C₆H₁₃NO
• Molecular Weight: 115.17352
• Mol File: 62367-59-3.mol

Chemical Properties

• Boiling Point: 177.6±0.0 °C(Predicted)
• Appearance: /
• Density: 1.005±0.06 g/cm3(Predicted)
• PKA: 14.95±0.20(Predicted)
• CAS DataBase Reference: (S)-3-Hydroxy-1-methyl-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-Hydroxy-1-methyl-piperidine(62367-59-3)
• EPA Substance Registry System: (S)-3-Hydroxy-1-methyl-piperidine(62367-59-3)

Safety Data

• Hazardous Substances Data: 62367-59-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-Hydroxy-1-methyl-piperidine is used as a pharmaceutical intermediate for the synthesis of various drugs and biologically active compounds. Its unique structural features and reactivity in chemical reactions make it a valuable component in the development of new medications and therapeutic agents.
Used in Research and Development:
In the field of research and development, (S)-3-Hydroxy-1-methyl-piperidine serves as a key compound for exploring its potential pharmacological applications. Further studies and testing are necessary to understand its full range of uses and effects, which may lead to the discovery of novel treatments and advancements in medicine.

Upstream product

• 475058-41-4 (S)-3-hydroxypiperidine hydrochloride 
• 50-00-0 formaldehyd 
• 99176-14-4 1-methyl-3-piperidinyl butyrate 
• 3554-74-3 3-Hydroxy-1-methylpiperidine 
• 108-05-4 vinyl acetate 
• 6659-33-2 (±)-3-acetoxy-N-methylpiperidine 
• 5519-50-6 1-methyl-3-piperidone 

Downstream Products

• 1428555-21-8 C₁₃H₁₅F₃N₂O₃ 
• 1428555-13-8 C₂₁H₂₄BrF₃N₂O₅S 
• 1613045-94-5 (S)-1-methylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate 

Relevant articles and documents

Implementation of biocatalysis in continuous flow for the synthesis of small cyclic amines

Significant progress has been made in establishing transaminases as robust biocatalysts for the green and scalable synthesis of a diverse range of chiral amines.[1] However, very few examples on the amination of small cyclic ketones have been reported.[2] Cyclic ketones are particularly challenging for transaminase enzymes because they do not display the well-defined small and large substituent areas that are characteristic for the biocatalytic mechanism. In this work, we exploited the broad substrate scope of the (S)-selective transaminase from Halomonas elongata (HeWT) to develop an efficient biocatalytic system in continuous flow to generate a range of small cyclic amines which feature very often in pharmaceuticals and agrochemicals.[3] Tetrahydrofuran-3-one and other challenging prochiral ketones were rapidly (5-45 min) transformed to their corresponding amines with excellent molar conversion (94-99%) and moderate to excellent ee.

Widely applicable background depletion step enables transaminase evolution through solid-phase screening

Directed evolution of transaminases is a widespread technique in the development of highly sought-after biocatalysts for industrial applications. This process, however, is challenged by the limited availability of effective high-throughput protocols to evaluate mutant libraries. Here we report a rapid, reliable, and widely applicable background depletion method for solid-phase screening of transaminase variants, which was successfully applied to a transaminase from Halomonas elongata (HEWT), evolved through rounds of random mutagenesis towards a series of diverse prochiral ketones. This approach enabled the identification of transaminase variants in viable cells with significantly improved activity towards para-substituted acetophenones (up to 60-fold), as well as tetrahydrothiophen-3-one and related substrates. Rationalisation of the mutants was assisted by determination of the high-resolution wild-type HEWT crystal structure presented herein.

Preparation of (R)-3-hydroxy-n-methylpiperidine, a synthetic key intermediate of (R)-mepenzolate, based on the lipase-catalyzed resolution of the racemic form

In this study, a two-step method for the gram-scale synthesis of (R)-3-hydroxy-N-methylpiperidine in 97.8% enantiomeric excess (ee) is reported. The key chiral synthetic intermediate of (R)-mepenzolate was formed in 22% yield over two steps using a commer

Simple one-pot process for the bioresolution of tertiary amino ester protic ionic liquids using subtilisin

An efficient hydrolase-catalyzed bioresolution of tertiary amino ester protic ionic liquids has been demonstrated. Protic ionic liquids have been prepared in one step from the corresponding tertiary amino alcohols by treatment with butyric anhydride. Afte

Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators

The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.